DODGX
Price
$17.18
Change
+$0.13 (+0.76%)
Updated
Jun 12 closing price
Net Assets
119.19B
SLVRX
Price
$43.20
Change
+$0.49 (+1.15%)
Updated
Jun 12 closing price
Net Assets
3.09B
Interact to see
Advertisement

DODGX vs SLVRX

Header iconDODGX vs SLVRX Comparison
Open Charts DODGX vs SLVRXBanner chart's image
DODGX vs SLVRX Comparison Chart in %
View a ticker or compare two or three
VS
DODGX vs. SLVRX commentary
Jun 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DODGX is a Buy and SLVRX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
DODGX has more cash in the bank: 119B vs. SLVRX (3.09B). DODGX pays higher dividends than SLVRX: DODGX (1.24) vs SLVRX (1.03). DODGX was incepted earlier than SLVRX: DODGX (61 years) vs SLVRX (23 years). SLVRX (1.32) is less costly to investors than DODGX (0.51). SLVRX is a more actively managed with annual turnover of: 28.00 vs. DODGX (20.00). SLVRX has a lower initial minimum investment than DODGX: SLVRX (0) vs DODGX (2500). SLVRX annual gain was more profitable for investors over the last year : 26.50 vs. DODGX (17.64). DODGX return over 5 years is better than : 159.37 vs. SLVRX (48.71).
DODGXSLVRXDODGX / SLVRX
Total Expense Ratio0.511.1046%
Annual Report Gross Expense Ratio0.511.3239%
Fund Existence61 years23 years-
Gain YTD3.87614.16527%
Front LoadN/AN/A-
Min. Initial Investment25000-
Min. Initial Investment IRAN/AN/A-
Net Assets119B3.09B3,851%
Annual Yield % from dividends1.241.03120%
Returns for 1 year17.6426.5067%
Returns for 3 years129.4754.30238%
Returns for 5 years159.3748.71327%
Returns for 10 years489.57128.17382%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HYPD2.720.06
+2.26%
Hyperion DeFi Inc
FIVN21.230.40
+1.92%
Five9
GAP21.890.03
+0.14%
Gap Inc (The)
MMTXU10.10N/A
N/A
Miluna Acquisition Corp
CATX2.95-0.02
-0.67%
Perspective Therapeutics